Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediate-term efficacy, including virologic, biochemical, serologic, an...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Association for the Study of the Liver
2021-07-01
|
| Series: | Clinical and Molecular Hepatology |
| Subjects: | |
| Online Access: | http://e-cmh.org/upload/pdf/cmh-2021-0179.pdf |
| _version_ | 1819098547906150400 |
|---|---|
| author | Sung Won Lee Jonggi Choi Seung Up Kim Young-Suk Lim |
| author_facet | Sung Won Lee Jonggi Choi Seung Up Kim Young-Suk Lim |
| author_sort | Sung Won Lee |
| collection | DOAJ |
| description | Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediate-term efficacy, including virologic, biochemical, serologic, and histologic responses. However, huge controversies regarding the antiviral efficacy of ETV and TDF in preventing the development of hepatocellular carcinoma (HCC) still exist. In this review, we summarized recent studies that compared the treatment efficacy of ETV and TDF in terms of HCC development. |
| first_indexed | 2024-12-22T00:32:44Z |
| format | Article |
| id | doaj.art-10448268416c4ebbb8589720693b347f |
| institution | Directory Open Access Journal |
| issn | 2287-2728 2287-285X |
| language | English |
| last_indexed | 2024-12-22T00:32:44Z |
| publishDate | 2021-07-01 |
| publisher | Korean Association for the Study of the Liver |
| record_format | Article |
| series | Clinical and Molecular Hepatology |
| spelling | doaj.art-10448268416c4ebbb8589720693b347f2022-12-21T18:44:53ZengKorean Association for the Study of the LiverClinical and Molecular Hepatology2287-27282287-285X2021-07-0127340241210.3350/cmh.2021.01791621Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinomaSung Won Lee0Jonggi Choi1Seung Up Kim2Young-Suk Lim3 Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seou, Korea Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seou, KoreaOver the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediate-term efficacy, including virologic, biochemical, serologic, and histologic responses. However, huge controversies regarding the antiviral efficacy of ETV and TDF in preventing the development of hepatocellular carcinoma (HCC) still exist. In this review, we summarized recent studies that compared the treatment efficacy of ETV and TDF in terms of HCC development.http://e-cmh.org/upload/pdf/cmh-2021-0179.pdfentecavirtenofovirhepatitis bcarcinoma, hepatocellularefficacyoutcome |
| spellingShingle | Sung Won Lee Jonggi Choi Seung Up Kim Young-Suk Lim Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma Clinical and Molecular Hepatology entecavir tenofovir hepatitis b carcinoma, hepatocellular efficacy outcome |
| title | Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma |
| title_full | Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma |
| title_fullStr | Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma |
| title_full_unstemmed | Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma |
| title_short | Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma |
| title_sort | entecavir versus tenofovir in patients with chronic hepatitis b enemies or partners in the prevention of hepatocellular carcinoma |
| topic | entecavir tenofovir hepatitis b carcinoma, hepatocellular efficacy outcome |
| url | http://e-cmh.org/upload/pdf/cmh-2021-0179.pdf |
| work_keys_str_mv | AT sungwonlee entecavirversustenofovirinpatientswithchronichepatitisbenemiesorpartnersinthepreventionofhepatocellularcarcinoma AT jonggichoi entecavirversustenofovirinpatientswithchronichepatitisbenemiesorpartnersinthepreventionofhepatocellularcarcinoma AT seungupkim entecavirversustenofovirinpatientswithchronichepatitisbenemiesorpartnersinthepreventionofhepatocellularcarcinoma AT youngsuklim entecavirversustenofovirinpatientswithchronichepatitisbenemiesorpartnersinthepreventionofhepatocellularcarcinoma |